surmount study tirzepatide SURMOUNT‐4 design. This is a phase 3, multicenter, randomized, Tirzepatide after intensive lifestyle intervention
Description
Concurrent use of prednisone and tirzepatide requires careful clinical oversight due to opposing metabolic effects
95% CI 0.97, 1.15)
Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population
Yet another study showing high discontinuation rate of both semaglutide and tirzepatide up to 50% at 1 year in the real world
